deltatrials
Terminated INTERVENTIONAL NCT05826600

A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

A Phase I/Ib Dose Escalation and Cohort Expansion Study of OMX-0407 a Salt-inducible Kinase Inhibitor in Patients With Previously Treated Unresectable Solid Tumours

Sponsor: iOmx Therapeutics AG

Conditions Solid Tumor
Interventions OMX-0407
Updated 15 times since 2023 Last updated: Apr 21, 2026 Started: Mar 30, 2023 Primary completion: Apr 2, 2026 Completion: Apr 2, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated as part of strategic considerations and not based on safety concerns.

Other Solid Tumor trials with similar outcome

Browse all Solid Tumor trials

This observational or N/A phase trial investigates Solid Tumor and is currently terminated or withdrawn. iOmx Therapeutics AG leads this study, which shows 15 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Jun 2024 · 6 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – ~Apr 2026 · 3 months · monthly snapshotApr 28, 2026 – present · 2 months · daily API

Change History

15 versions recorded

  1. Apr 28, 2026 — Present [daily]

    Terminated

    Status: Active Not Recruiting → Terminated · Phase: PHASE1/PHASE2 → None

  2. Feb 2026 — Apr 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2025 — Feb 2026 [monthly]

    Recruiting PHASE1/PHASE2

  4. Mar 2025 — Sep 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 10 earlier versions

  1. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE1/PHASE2

  2. Oct 2024 — Jan 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  6. Dec 2023 — Jun 2024 [monthly]

    Recruiting PHASE1

  7. Sep 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  8. Jul 2023 — Sep 2023 [monthly]

    Recruiting PHASE1

  9. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1

  10. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

    First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

The main purpose of the dose escalation phase of the study is to determine the safety of different doses of OMX-0407. The dose expansion (phase Ib) part of the study will evaluate efficacy, safety and tolerability at a dose determined in the dose escalation,

Contact Information

Sponsor contact:
  • iOmx Therapeutics AG
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Barcelona, Spain , Barcelona, Spain , Bordeaux, France , Brussels, Belgium , Ghent, Belgium , L'Hospitalet de Llobregat, Spain , Liège, Belgium , Lyon, France , Madrid, Spain and 14 more locations